HomeGrants › PAR-28-043

Forecasted

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development

Federal funding opportunity PAR-28-043 from National Institutes of Health.

View forecast on Grants.gov →Forecasted — not yet open

Posted
July 7, 2026
Closes
See announcement
Expected awards
4
Cost sharing
No
Instrument
Cooperative Agreement
Assistance listing
93.853
Category
Health

Program funding history

Awards made under Assistance Listing 93.853 across FY2024–FY2026, from public federal spending records.

FY2024 obligated
$1.8B
FY2025 obligated
$1.8B
FY2026 (to date) obligated
$1B
Awards in window
9,367

Top recipients: The General Hospital Corporation, Regents of the University of California, San Francisco, the, The Johns Hopkins University, Regents of the University of Michigan, The Trustees of Columbia University in the City of New York

Source: USAspending.gov · refreshed July 2026

Synopsis

The NIH Blueprint for Neuroscience Research is interested in continuing to support the BluePrint Neurotherapeutics Network for Small Molecules (BPN-SM)- a program designed to help investigators advance promising small-molecule therapeutics toward clinical testing. The BPN-SM program supports drug discovery and development activities in investigators’ own laboratories while also providing access to NIH-supported subject matter experts and contract research organizations (CROs) with capabilities in medicinal chemistry, pharmacokinetics, toxicology, formulation development, GMP synthesis, and Phase I clinical testing. By integrating NIH resources with industry-standard expertise, BPN-SM advances investigator-initiated drug discovery while enabling investigators to retain and strengthen their intellectual property while gaining hands-on experience in translational drug development.

The overarching goal of the program is to reduce the risk of scientific and therapy development sufficiently to enable external partners to take on late-stage development and ultimately bring new therapies to patients. In addition, this BPN program is specifically focused on small molecules and excludes biologics, because development, regulatory, and manufacturing considerations for each class of therapeutics differ substantially from each other. It will use a phased cooperative agreement mechanism which will enable the program to support innovative but higher-risk projects, with decisions of continued support being contingent on demonstrated feasibility of yearly milestones. A cooperative agreement framework is proposed because several key aspects of the program will involve collaborative activities between the investigators and NIH program staff, with substantial involvement beyond the normal scope of grant stewardship. The project principal investigator(s) and NIH program staff will work jointly with NIH-supported subject matter experts to coordinate and participate in all scientific and technical management aspects of the project.

Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop competitive projects and establish the cross-disciplinary collaborations necessary for success.

Who can apply

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

How to apply

Applications go through the official government listing. Grants Radar links you straight to the source.

View on Grants.gov

Agency contact: Blueprint Neurotherapeutics Team · BPNSMNINDS@mail.nih.gov · Please contact via e-mail

Get grants like this every Tuesday — free

One email a week: the biggest new federal grants and what’s closing soon. Unsubscribe in one click.

The free edition carries one clearly labeled sponsor slot. No spam, ever. Privacy

Similar grants

Never miss a funding deadline again

Grants Radar sends AI-enriched alerts on federal grants and contracts matched to what you do. Founding seats are limited and locked for life.

Get funding alerts